Genelux (GNLX) Enterprise Value (2022 - 2026)
Genelux (GNLX) recorded quarterly Enterprise Value of -$9.3 million in Q1 2026, down 74.39% quarter-over-quarter from -$5.3 million in Q4 2025, and up 32.61% on a YoY basis from -$7.0 million in Q1 2025.
Genelux (GNLX) Enterprise Value (2022 - 2026) Analysis & Trends
Genelux's Enterprise Value history runs 5 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 32.61% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$9.3 million (up 32.61% YoY), while the FY2025 annual figure was -$5.3 million, up 82.74% from the prior year.
- Enterprise Value was -$9.3 million for Q1 2026 at Genelux, down from -$5.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$397000.0 in Q4 2022 to a low of -$65.8 million in Q2 2024.
- Historically, Enterprise Value has averaged -$28.5 million across 5 years, with a median of -$25.8 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 5365.24% in 2023, then surged 82.74% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$397000.0 in 2022, then plunged by 5365.24% to -$21.7 million in 2023, then sank by 42.39% to -$30.9 million in 2024, then soared by 82.74% to -$5.3 million in 2025, then slumped by 74.39% to -$9.3 million in 2026.
- The last three Enterprise Value figures came in at -$9.3 million (Q1 2026), -$5.3 million (Q4 2025), and -$34.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.30 Mn |
| Dec 31, 2025 | -5.33 Mn |
| Sep 30, 2025 | -34.23 Mn |
| Jun 30, 2025 | -47.65 Mn |
| Mar 31, 2025 | -13.80 Mn |
| Dec 31, 2024 | -30.90 Mn |
| Sep 30, 2024 | -63.02 Mn |
| Jun 30, 2024 | -65.78 Mn |
| Mar 31, 2024 | -19.63 Mn |
| Dec 31, 2023 | -21.70 Mn |
| Sep 30, 2023 | -29.87 Mn |
| Dec 31, 2022 | -397,000.00 |